Hair Loss in Women is More Than a Cosmetic Concern
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
Atopic Dermatitis
FDA Grants Fast Track Designation to Orismilast for Atopic Dermatitis
The FDA’s Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
Worsening of Atopic Dermatitis During Pregnancy Uncommon
The prevalence and predictors of patient-reported worsening of AD symptoms during pregnancy are examined.
Oral and Topical Antifungals Beneficial for Dupilumab Facial Redness in Atopic Dermatitis
A novel study reports the positive response to oral and topical antifungals for patients with atopic dermatitis (AD) treated with dupilumab who developed facial redness.
Severe Atopic Dermatitis Tied to Mental Health Issues in Childhood
A possible link between childhood and adolescence atopic dermatitis and mental health issues in children is investigated.
Opzelura Cream Approved for Atopic Dermatitis
The Food and Drug Administration has approved Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. The approval was based on data…
Relative Safety of Systemic Immunomodulatory Agents for Atopic Dermatitis
The risk of bacterial and opportunistic infection in patients with AD treated with systemic immunomodulatory agents is assessed.
Skin Clearance, Itch Improvement Seen With Lebrikizumab in Atopic Dermatitis Trials
Lebrikizumab is a novel humanized monoclonal antibody that selectively inhibits IL-13.
Prenatal, Postnatal Antibiotic Exposure and Atopic Dermatitis in Children
A link between pre- and postnatal exposure to antibiotics and the risk for atopic dermatitis is investigated.
Atopic Dermatitis in Black Patients: Societal and Biologic Causes
Clinician competence in treating patients of various racial and ethnic backgrounds and the critical need for greater inclusion of diverse populations in trials investigating the pathophysiology and treatment of AD are underscored.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...